CERo Therapeutics Stock Surges 189.89% to 44th Most Actively Traded Amid FDA Orphan Drug Designation

On June 17, 2025, CERo Therapeutics (CERO) experienced a significant surge in trading volume, with a total turnover of 10.27 billion, marking a 36412.99% increase from the previous day. This substantial rise in trading volume positioned CERo as the 44th most actively traded stock of the day. The company's stock price soared by 189.89%, reflecting a strong market response to recent developments.

CERo Therapeutics received a significant boost when the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to its lead drug candidate, CER-1236. This designation is specifically for the treatment of acute myeloid leukemia, a type of cancer that affects the blood and bone marrow. The Orphan Drug Designation provides several benefits to CERo, including assistance in designing clinical trials, access to the FDA Orphan Drug Grants Program, and exemption from certain regulatory fees.

This designation is a crucial milestone for CERo Therapeutics, as it validates the potential of CER-1236 in addressing a critical unmet medical need. The FDA's recognition underscores the innovative nature of CERo's T cell therapy and its potential to improve outcomes for patients with acute myeloid leukemia. The market's positive reaction to this news is a testament to the significance of this achievement for the company and its investors.